论文部分内容阅读
目的探索建立嘉兴市梅毒(syphilis)反应性献血者归队检测方法,研究制定本市梅毒反应性献血者归队策略。方法对梅毒反应性献血者进行跟踪随访,在检验结果反应性暂时屏蔽一定时间(≥6个月)后将他们召回,采集血液标本,进行梅毒螺旋体酶联免疫吸附试验(TP-ELISA)、梅毒螺旋体颗粒凝集试验(TPPA)和TP DNA的检测,对结果进行分析,对复检结果符合现行国家标准《献血者健康检查要求》的献血者实施归队处理。结果 TPELISA检测53 531例献血者标本,其中ELISA双试剂阳性317例,TP-ELISA单试剂阳性标本217份,经TPPA试验阴性或不确定120份,联系到72例,实际前来血站检测28例。28例献血者半年后检测结果全部阴性,可以归队。结论建立了嘉兴市梅毒反应性献血者归队检测方案,对复检结果符合现行国家标准《献血者健康检查要求》的献血者实施归队处理(可以归队献血者28例)。探讨制定了本市梅毒反应性献血者归队策略,对于消除永久屏蔽对假阳性献血者身心造成的压力和伤害,缓解血液供需之间的矛盾,减少长期固定献血者的流失具有重大意义。
Objective To explore the establishment of detection methods of rehospitalization of syphilis-reactive blood donors in Jiaxing City, and to study the strategy of rehospitalization of syphilis-reactive blood donors in Jiaxing City. Methods The patients with syphilis-reactive blood donors were followed up. After the test results were temporarily shielded for more than 6 months, they were recalled, and blood samples were collected for TP-ELISA, syphilis Spirochel particle agglutination test (TPPA) and TP DNA test, the results were analyzed, the retest results in line with the current national standard “blood donors health check requirements” to implement the return of blood donors. Results TPAISA detected 53 531 blood donors, of which 317 were positive for ELISA and 217 were positive for TP-ELISA, and 72 were negative or uncertain by TPPA test. example. 28 cases of blood donors test results after six months all negative, you can rejoin. Conclusion The rehabilitative blood donor of syphilis was established in Jiaxing City, and the blood donors whose retest results conform to the current national standards of “Health Check for Blood Donors” were rehabilitated (28 blood donors could return to their blood donors). To explore the development of the city of syphilis reactive donor return strategy, to eliminate the permanent shield on the false positive blood donors physical and psychological stress and injury, to alleviate the contradiction between supply and demand of blood and reduce the loss of long-term fixed blood donors is of great significance.